<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">The biweekly PUL regimen consisted of cisplatin at 50 mg/m
 <sup>2</sup> on day 1 as well as tegafur-uracil (UFUR, TTY Biopharm Co. Ltd, Taipei, Taiwan) at 300 mg/m
 <sup>2</sup>/d and leucovorin at 60 mg/d on days 1–14 
 <xref rid="bib15" ref-type="bibr">[15]</xref>. The ICT/CCRT arm patients received ICT PUL every 2 weeks for 6 cycles, unless disease progression, unacceptable toxicity, withdrawal of patient consent, or stationary or progressive disease after 3 PUL cycles occurred. PUL was administered concurrently during CCRT in both arms. For patients with disease progression or unacceptable toxicity caused by ICT PUL, the CT regimens used for post-ICT CCRT were revised at the discretion of the physicians.
</p>
